The DOI matches its Crossref record; 61 of the 62 references it cites were found in a registry or an index.
Lecanemab: Appropriate Use Recommendations
Open accessAbstract
Lecanemab (Leqembi®) is approved in the United States for the treatment of Alzheimer's disease (AD) to be initiated in early AD (mild cognitive impairment [MCI] due to AD or mild AD dementia) with confirmed brain amyloid pathology. Appropriate Use Recommendations (AURs) are intended to help guide the introduction of new therapies into real-world clinical practice. Community dwelling patients with AD differ from those participating in clinical trials. Administration of lecanemab at clinical trial sites by individuals experienced with monoclonal antibody therapy also differs from the community clinic-based administration of lecanemab. These AURs use clinical trial data as well as research and care information regarding AD to help clinicians administer lecanemab with optimal safety and opportunity for effectiveness. Safety and efficacy of lecanemab are known only for patients like those participating in the phase 2 and phase 3 lecanemab trials, and these AURs adhere closely to the inclusion and exclusion criteria of the trials. Adverse events may occur with lecanemab including amyloid related imaging abnormalities (ARIA) and infusion reactions. Monitoring guidelines for these events are detailed in this AUR. Most ARIA with lecanemab is asymptomatic, but a few cases are serious or, very rarely, fatal. Microhemorrhages and rare macrohemorrhages may occur in patients receiving lecanemab. Anticoagulation increases the risk of hemorrhage, and the AUR recommends that patients requiring anticoagulants not receive lecanemab until more data regarding this interaction are available. Patients who are apolipoprotein E ε4 (APOE4) gene carriers, especially APOE4 homozygotes, are at higher risk for ARIA, and the AUR recommends APOE genotyping to better inform risk discussions with patients who are lecanemab candidates. Clinician and institutional preparedness are mandatory for use of lecanemab, and protocols for management of serious events should be developed and implemented. Communication between clinicians and therapy candidates or those on therapy is a key element of good clinical practice for the use of lecanemab. Patients and their care partners must understand the potential benefits, the potential harms, and the monitoring requirements for treatment with this agent. Culture-specific communication and building of trust between clinicians and patients are the foundation for successful use of lecanemab.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Lecanemab has a boxed warning for serious and symptomatic ARIA and requires testing for APOE ε4 prior to initiation as homozygosity increases risk.(510)”
From Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission (2024) · cites this paper as [510]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Currently, anti-amyloid monoclonal antibodies require the confirmation of amyloid-β pathology from PET or CSF before initiating therapy45,46.”
From Diagnosis of Alzheimer's disease using plasma biomarkers adjusted to clinical probability (2024) · cites this paper as [45]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For example, although patients with early-stage AD may be candidates for anti-amyloid therapies15–17, the coexistence of pathology from other etiologies, such as VD, can increase the risk of amyloid-related imaging abnormalities18.”
From AI-based differential diagnosis of dementia etiologies on multimodal data (2024) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The risk of developing these potentially serious adverse effects is higher in APOEε4 carriers, particularly homozygotes, and current recommendations are that patients are genotyped for APOE before starting these therapies to offer a balanced benefit–risk discussion190.”
From Multifaceted roles of APOE in Alzheimer disease (2024) · cites this paper as [190]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Plasma biomarkers may therefore have an important role in reducing the patient burden associated with the initiation of anti-amyloid-β therapies for AD, which at present require biomarker confirmation with PET or CSF, as well as serial magnetic resonance imaging to monitor for adverse events45,46.”
From Diagnosis of Alzheimer's disease using plasma biomarkers adjusted to clinical probability (2024) · cites this paper as [45]
The cited source says what the claim attributes to it.
In the citing paper
“Individuals with two copies of the APOE‐e4 gene are at increased risk of developing ARIA.”
From 2024 Alzheimer's disease facts and figures (2024) · cites this paper as [59]
The cited source says what the claim attributes to it.
In the citing paper
“Accordingly, ApoE genotyping is now increasingly considered an important component of the pre-treatment work-up for anti-amyloid therapies [5, 8, 11, 12].”
From Plasma ApoE proteotyping for ApoE ε4 stratification in the anti-amyloid therapies era (2026) · cites this paper as [11]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
Hirono, N., Mori, E., Ikejiri, Y., Imamura, T., Shimomura, T., Hashimoto, M., Yamashita, H., & Ikeda, M. (1997) · PubMed · Cited by 21,012
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Older Adults' Reasons for Using Technology while Aging in Place
Peek, S. T. M., Luijkx, K. G., Rijnaard, M. D., Nieboer, M. E., van der Voort, C. S., Aarts, S., van Hoof, J., Vrijhoef, H. J., & Wouters, E. (2015) · Gerontology · doi:10.1159/000430949 · Cited by 19,852
Sensitivity and False Alarm Rate of a Fall Sensor in Long-Term Fall Detection in the Elderly
Kangas, M., Korpelainen, R., Vikman, I., Nyberg, L., & Jämsä, T. J. (2014) · Gerontology · doi:10.1159/000362720 · Cited by 19,007
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152
Self-citationLecanemab in early Alzheimer's disease
van Dyck, C. H., Swanson, C. J., Aisen, P., Bateman, R. J., Chen, C., Gee, M., Kanekiyo, M., Li, D., Reyderman, L., Cohen, S., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2212948 · Cited by 5,678
Self-citationMR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging
Fazekas, F., Chawluk, J. B., Alavi, A. A., Hurtig, H. I., & Zimmerman, R. A. (1987) · American Journal of Roentgenology · doi:10.2214/ajr.149.2.351 · Cited by 5,327
Preclinical Alzheimer’s Disease: Definition, Natural History, and Diagnostic Criteria
Dubois, B., Hampel, H., Feldman, H. H., Scheltens, P., Aisen, P., Andrieu, S., Bakardjian, H., Benali, H., Bertram, L., Blennow, K., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.02.002 · Cited by 1,925
Self-citation
Flagged first, then by citations
1 of the 62 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Irizarry M, van Dyck C, Sabbagh M, Bateman RJ, S. C, editors. Clarity AD: A phase 3 placebo-controlled, double-blind, parallel-group, 18-month study evaluating lecanemab in early Alzheimer's disease. 15th Clinical Trials on Alzheimer's Disease Conference; 2022; San Francisco, CA USA.
Cited by
Sorted by citations
Items 701–800 of 961
Genomics and Transcriptomics of Alzheimer Disease
Vilor‐Tejedor, N., Rodríguez‐Fernández, B., Genius, P., Luckett, E. S., Anastasi, F., Lorenzini, L., Murray, H., Bull, C. J., Clement, M. H. S., Morris, A., et al. (2025) · Springer eBooks · doi:10.1007/978-3-031-80849-4_13
Living with Neurodegenerative Disorders: Management, Support, and Hope
Kajrolkar, A. (2025) · Premier Journal of Biomedical Science · doi:10.70389/pjbs.100006
Block, F. (2025) · DGNeurologie · doi:10.1007/s42451-025-00782-4
Lecanemab (▼Leqembi) for Alzheimer’s disease
BMJ Publishing Group Ltd (2025) · Drug and Therapeutics Bulletin · doi:10.1136/dtb.2024.000057
Sideman, A. B., Alagappan, C., Arteaga, I., Breithaupt, A. G., Soleymani, S., Belani, H., Pham, T., Pak, S., Sigala, T., Gravano, J. T., et al. (2026) · BMC Family Practice · doi:10.1186/s12875-026-03437-9
Ismail, Z., Wilson, M., Khalifa, H., Belovich, D., Shaw, E., Pham, T., McMullen, S., Chen, Y., Sadman, N., Cai, J., et al. (2025) · Journal of Primary Care & Community Health · doi:10.1177/21501319251363156 · Cited by 1
Fong, J. C., Chavez, F. I., Silos, K., Arroyo‐Miranda, M. L., Castro, G. C., Kunik, M. E., Shulman, J. M., & Medina, L. D. (2025) · medRxiv · doi:10.1101/2025.08.19.25334002
Sato, K., Nakashima, S., Niimi, Y., Ihara, R., & Iwatsubo, T. (2025) · Journal of Alzheimer s Disease Reports · doi:10.1177/25424823251372925
Flanagan, B., Lynch, J., Kakar, S., McGuinness, B., Patterson, K., Passmore, A. P., & Cunningham, E. L. (2025) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.70149
Ransmayr, G. N., Eicher, E., Mraczansky, J., Braoudaki, E., Defrancesco, M., Struhal, W., Bancher, C., Dal‐Bianco, P., Marksteiner, J., Schmidt, R., et al. (2025) · Wiener klinische Wochenschrift · doi:10.1007/s00508-025-02608-5
EFFECTIVENESS OF LECANEMAB AND DONANEMAB TREATMENT FOR EARLY ALZHEIMER’S DISEASE
Ufniarska, M., Ufniarski, T., Piech, A., Pasierb, K., Poplicha, K., Grodzińska, M., Siuzdak, B., Moszkowicz, J., Sobkiewicz, P., Kardasz, P., et al. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(47).2025.3751
Nencha, U., & Hummel, F. C. (2025) · Clinical and Translational Neuroscience · doi:10.3390/ctn9030043
Clonal expansion of cytotoxic CD8 + T cells in lecanemab-associated ARIAPreprint
Johnson, L. A., Saito, K., Pallerla, A. V., Funnell, J. L., Ezzo, A. R., Song, C. L., Harrison, D. A., Norton, N. J., Moore, L. C., Eldik, L. J. V., et al. (2025) · medRxiv · doi:10.1101/2025.09.17.25335728
Five-Year Trajectory of Mild Cognitive Impairment: Insights from a Primary Care Memory Clinic
Lee, L. S., Jones, A., Patel, T., Hillier, L. M., Parikh, R., Lee, C., Ismail, Z., Molnar, F., & Chertkow, H. M. (2025) · Canadian Journal on Aging / La Revue canadienne du vieillissement · doi:10.1017/s0714980825100299
Augmenting radiological assessment of imaging evident dementias with radiomic analysis
Puducheri, S., Zhou, O. T., Kapadia, K., Romano, M. F., Yalamanchili, S., Agrawal, A., Arasa, V. C. A., Farris, C. W., Mian, A. Z., Paul, A. B., et al. (2025) · npj Dementia · doi:10.1038/s44400-025-00031-1 · Cited by 1
Navia, A. M., López, A., Álvarez‐Sánchez, L., Ferré‐González, L., Balaguer, Á., Baquero, M., & Cháfer‐Pericás, C. (2025) · Journal of Personalized Medicine · doi:10.3390/jpm15100475
Sato, K., Ihara, R., Niimi, Y., Suzuki, K., Iwata, A., Iwatsubo, T., & Initiative, F. J. A. D. N. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251385119
Wang, J., Zhong, A., Xu, Q., Huang, H., Zhu, Y., Lu, J., Wang, M., Jiang, J., Li, C., Ni, M. A., et al. (2025) · medRxiv · doi:10.1101/2025.10.20.25338339
APOE ε4 and ischemic heart disease in American Indian/Indigenous tribal Elders
Labounek, R., Matheson, M. J., Petersen, A. J., Hansen, A., Block, A. D., Strong, C., Hill, A., Kremer, M., Robertson, A. J., Maharaj, V., et al. (2025) · American Heart Journal Plus Cardiology Research and Practice · doi:10.1016/j.ahjo.2025.100662
Treatment of Alzheimer’s Disease
Cummings, J. L. (2025) · Cambridge University Press eBooks · doi:10.1017/9781108985055.021
Self-citationApoe genotype knowledge and its impact on cognitive beliefs and performance
Barber, S. J., Menon, M., Shoemaker, K. J., Mather, M., Langbaum, J. B. S., & Karlawish, J. H. (2025) · Aging Neuropsychology and Cognition · doi:10.1080/13825585.2025.2587702
Lecanemab for posterior cortical atrophy: Two contrasting cases
Katsuse, K., Kakinuma, K., Niimi, Y., Iseki, C., Kawakami, N., Ota, S., Kawamura, A., Ogawa, N., Yano, S., Kakumoto, T., et al. (2025) · The Clinical Neuropsychologist · doi:10.1080/13854046.2025.2590527
Kabachna, I. V., Filova, A. S., & Kabachnyy, V. I. (2025) · Psychiatry Neurology and Medical Psychology · doi:10.26565/2312-5675-2025-31-08
Healy, M., Thomas, S. T., & Brodtmann, A. G. (2025) · Internal Medicine Journal · doi:10.1111/imj.70254
APOE and Genetic Counseling for Dementia in Clinical Practice
Rumbaugh, M. C., & Chan, A. K. (2025) · Springer eBooks · doi:10.1007/978-3-031-52641-1_71-1
Alzheimer’s Biochemistry and Therapeutic Prospects of Functional Foods-based Strategies
Akanbi, C. A., Akanji, M. A., & Adeyemı, O. S. (2025) · The Open Biochemistry Journal · doi:10.2174/011874091x416492251129102634
Current therapies for the treatment of Alzheimer's disease
Finn, L. A. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-30008-0.00007-7
Sato, K., Niimi, Y., Iwatsubo, T., & Initiative, A. D. N. (2025) · Alzheimer s & Dementia Behavior & Socioeconomics of Aging · doi:10.1002/bsa3.70052
Kamitaka, Y., Sakata, M., Oda, K., Katsuki, A., Kawakami, H., Wagatsuma, K., Kobayashi, M., & Ishii, K. (2025) · EJNMMI Physics · doi:10.1186/s40658-025-00820-w
Arican, I., van der Horst, M. Z., Bass, N. J., & Zinkstok, J. (2025) · Psychiatric Genetics · doi:10.1097/ypg.0000000000000407
(2025) · Oxford University Press eBooks · doi:10.1093/med/9780198869696.003.0023
Pérez, S. S., Bringas, G., Amable, N. U., Peñalver, A. I., López, D., González, E. J., Fernández, A., Hernández, Z. M., Viña, A., Peña, Y., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26653149
Einsatz von Amyloid-β-Antikörpern in der klinischen Praxis
Duning, T., & Südmeyer, M. (2025) · NeuroTransmitter · doi:10.1007/s15016-025-4104-y
NEW PERSPECTIVES ON ALZHEIMER’S DISEASE TREATMENT: A STRUCTURED SCIENTIFIC REVIEW (2020–2025)
Wilska, H., Liebert, A., Klimek, N., Niedziela, A., Domoń, D., Kaplińska, M., & Domanowska, D. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(47).2025.3854
Parks, A. L., Lykken, J. M., Rieu‐Werden, M. L., Ko, D., Kim, D., Fang, M. C., Greenberg, S. M., Witt, D. M., Supiano, M. A., & Shah, S. J. (2025) · Alzheimer s & Dementia · doi:10.1002/alz70860_103167
Self-citationPark, S. H., Suh, J., & Roh, J. H. (2025) · Journal of Korean Medical Association · doi:10.5124/jkma.25.0141
Verma, K., & Kumar, S. (2025) · medRxiv · doi:10.64898/2025.12.20.25342753
Sen, S. E. (2025) · medRxiv · doi:10.64898/2025.12.30.25343198 · Cited by 1
Giuffrè, G. M., Battisti, F., Tudor, A. M., Lenkowicz, J., Avitabile, A., Rosati, A. M., Martellacci, N., Patarnello, S., Torelli, F., Cesario, A., et al. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877251411461
Mental health symptoms as preclinical indicators of dementia: a Whitehall II cohort studyPreprint
Iyer, M. T., Fayossé, A., Mika Kivimaki, B., Livingston, G., Singh‐Manoux, A., Warren‐Gash, C., Sommerlad, A., & Sabia, S. (2026) · medRxiv · doi:10.64898/2026.01.08.26343594
Pharmacological Precision Medicine to Treat Dementia
Lee, K., Lin, P., Wu, M.-J., & Sung, P. (2026) · Springer eBooks · doi:10.1007/978-981-95-5222-1_9
Sato, K., 芳樹, 新., Kurihara, M., Ihara, R., Iwata, A., & Iwatsubo, T. (2026) · Journal of Aging Research and Lifestyle · doi:10.1016/j.jarlif.2026.100059
Roy, D., Kakoti, B. B., & Rymbai, E. (2026) · Discover Chemistry. · doi:10.1007/s44371-026-00508-9
Cost‐effectiveness and impact at scale of collaborative care and lecanemab for Alzheimer's disease
Atkins, K. J., Kahn, J. G., & Possin, K. L. (2026) · Alzheimer s & Dementia Behavior & Socioeconomics of Aging · doi:10.1002/bsa3.70054
Radiofrequency electromagnetic fields in Alzheimer’s therapy: emerging evidence and future prospects
Liu, W., Rao, X., Sun, W., Chen, X., Yu, L., & Zhang, J. (2026) · Electromagnetic Biology and Medicine · doi:10.1080/15368378.2026.2627962
Janicki, M. P., McCallion, P., Jokinen, N. S., Larsen, F., Mughal, D. T., Service, K. P., Gomiero, T., Marsack‐Topolewski, C. N., Watchman, K., Santos, F. H., et al. (2026) · Autism · doi:10.1177/13623613261416670
Pikus, P., Healey, G. S., Xia, E., Shautidze, G., Siddapureddy, N., Lee, Y., Albanese, C., Rodriguez, O. C., Turner, R. S., & Rebeck, G. W. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.09.704876
Low number of patients qualifying for amyloid targeting immunotherapy
Jessen, F. (2026) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2026.100516
Miyazaki, K., MORITA, H., & Ishii, K. (2026) · Acta Neurochirurgica · doi:10.1007/s00701-026-06804-8
Chauhan, M., Singh, K. P., & Sharma, P. (2026) · iScience · doi:10.1016/j.isci.2026.115181
Hypoperfusion in early-phase amyloid PET as a predictor of cognitive decline in Alzheimer's disease
Škorvagová, A., Ribaldi, F., Cerman, J., Wang, C., Scheffler, M., Mendes, A. J., Wyss‐Dominguez, C., Garibotto, V., Frisoni, G. B., Andel, R., et al. (2026) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-025-07694-1
Parnetti, L., & Gaetani, L. (2026) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2026.101631
Accountable Care, Prescription Access, Tradeoffs, and System Resilience in Early ADRD
Jang, S., & (5892), J. C. (2026) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2026.02.013
Shin, H., Lee, S., Seo, W., Yoon, S. H., Cho, I., Ye, S., Park, I., Yoon, S., Park, M., Kim, S., et al. (2026) · Alzheimer s Research & Therapy · doi:10.1186/s13195-026-01999-5
Vejdani‐Jahromi, M., Calle, E., Chagui, O. G., Rohatgi, S., Farzaneh, H., Griffin, H., Zhu, S., Seah, J. C. Y., Omid‐Fard, N., Kozak, B. M., et al. (2026) · American Journal of Neuroradiology · doi:10.3174/ajnr.a9056
Thacker, A., Parks, A. L., Dohan, D. P., Gomez, L. A. R., Ritchie, C. S., Shah, S., Gale, S. A., & Paladino, J. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261422486 · Cited by 1
Verma, K., & Kumar, S. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261430858
Accelerated 3D MRI for ARIA monitoring in Alzheimer's disease
Rosa‐Grilo, M., Mallon, D. H., Thomas, D. L., Beament, M., Chughtai, H. R., Liu, W., Magill, N., Malone, I. B., Meyer, H., Parker, G. J. M., et al. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71297
Dangpiaei, S., Kamal, K. M., Shoair, O. A., & Al-Mamun, M. A. (2026) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2026.32.4.470 · Cited by 1
Aligning Alzheimer Trials With Disease Demographics—From Rhetoric to Reality
Bubu, O. M. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.2373
NEW DISEASE-MODIFYING THERAPIES IN ALZHEIMER’S DISEASE: A CLINICAL REVIEW OF LECANEMAB AND DONANEMAB
Ollik, K., Harenza, K., Taranowicz, M., Kowalczyk, O., Zdobylak, D., Kowalska, M., Zieba, A., Domin, M., Całka, J., & Ścibisz, K. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.1(49).2026.4885
Prelog, P. R., Plesničar, B. K., Zupan, M., Frol, S., & Kramberger, M. G. (2026) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2026.2653170
Health system patterns of imaging and fluid biomarker testing in the era of anti‐amyloid therapies
Robb, W. H., Kaur, G., Huang, S. K., Martinez, F., Nguyen, B. D., Shin, C., Yang, M., Conyers, C. T., Grilli, C. B., Upjohn, D. P., et al. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71343
Genkwanin Facilitates Long-term Potentiation via Calcium-permeable AMPA Receptor in the Hippocampus
Kim, C., Moon, S., & Kim, D.-H. (2026) · 생약학회지 · doi:10.22889/kjp.2026.57.1.18
Fong, J. C., Chavez, F. I., Silos, K., Arroyo‐Miranda, M. L., Castro, G. C., Kunik, M. E., Shulman, J. M., & Medina, L. D. (2026) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.70241
Kaur, N., Gupta, S., Bansal, G., & Bansal, Y. (2026) · Molecular Diversity · doi:10.1007/s11030-026-11546-x · Cited by 2
Olson, C., Bravo, M. M. G., González, G., & Camp, M. E. (2026) · Focus · doi:10.1176/appi.focus.20250042
Advances in Psychopharmacology: What Clinicians Need to Know
(2026) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.26024109
From mechanisms to therapeutics: The expanding role of cell-based strategies in Alzheimer's disease
Sun, X., Deng, W., Yu, J., & Xu, X. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.178867
Yang, B., Earnest, T., Bilgel, M., Albert, M., Johnson, S. C., Davatzikos, C. A., Erus, G., Masters, C. L., Resnick, S. M., Miller, M. I., et al. (2026) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2026.04.005
Benefits and Harms of Dementia Screening for Family Members of Older Adults
Fowler, N. R., Perkins, A. J., Gao, S., Bakas, T., Head, K. J., Higbie, A., Baucco, C., Callahan, C. M., Williams-Farrelly, M. M., & Boustani, M. A. (2026) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2026.0844
Singh, S., Jindal, D., Haque, M. M. U., Kapoor, M., & Singh, M. (2026) · BIO Web of Conferences · doi:10.1051/bioconf/202623301004
Huang, Y., Li, Q., Chen, A., Li, Y., Chuang, Y.-N., Hu, X., Guo, S. J., He, X., Pang, Y., Zhou, J., et al. (2026) · JAMIA Open · doi:10.1093/jamiaopen/ooag060 · Cited by 2
Fawad, A., van der Landen, S. M., Tideman, P., van der Putten‐Toorenburg, A., Butterbrod, E., Smith, R. A., van Westen, D., Calling, S., Midlöv, P., Mattsson, N., et al. (2026) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.70344
Dementia screening with the Rivermead Behavioural Memory Test: A machine learning analysis
Fujiwara, Y., Toyoda, K., Maruyama, S., Kitano, M., Toda, H., & Kanazawa, T. (2026) · Journal of Alzheimer's Disease · doi:10.1177/13872877261443699
Lee, J., Kim, H., Park, H. K., Kim, S., Lee, K. B., Kang, H., Shin, D., Kim, J. P., & Lee, B. H. (2026) · Dementia and Neurocognitive Disorders · doi:10.12779/dnd.2026.25.2.134
Kim, H., Lee, J., Park, H. K., Lee, K. B., Kim, J. P., & Lee, B. H. (2026) · Dementia and Neurocognitive Disorders · doi:10.12779/dnd.2026.25.2.137
Exalto, L. G., Syaziyah, S. S., Fang, X. T., Prins, N. D., Sikkes, S. A. M., van der Flier, W. M., Vijverberg, E. G. B., & Lim, Y. M. F. (2026) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2026.100580
Bailey-Taylor, M. J., Morrow, P., Hendrix, J., Galluzzi, K. E., & Sharafsaleh, G. (2026) · Clinical Interventions in Aging · doi:10.2147/cia.s585263
Interchangeability of CSF and PET to identify Alzheimer's disease pathology
Burnham, S. C., Arora, A., Iaccarino, L., Kennedy, I. A., Kotari, V., Wijayawardana, S. R., Shaw, L. M. J., Benina, N., Lu, M., Pontecorvo, M. J., et al. (2026) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.70288
Kynčl, M., Cihlář, F., Vymazal, J., Ryška, P., Mechl, M., & Ferda, J. (2026) · Česká radiologie · doi:10.55095/cesradiol2026/015
Weitzel, M., Walendzik, A., Giebel, G. D., Raszke, P., Wasem, J., Levin, J., Nübling, G., Wagemann, O., Wlasich, E., Pantel, J., et al. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261449417
Morimoto, S., Takahashi, S., & Okano, H. (2026) · Japanese Journal of Radiology · doi:10.1007/s11604-026-02000-x
Sánchez‐Valle, R., Alcolea, D. A., Ferrer, G. A., Balasa, M., Naranjo, I. C., Fortea, J., Lladó, A., Lleó, A., Montes, A. M., Lozano, L. M., et al. (2026) · Neurología · doi:10.1016/j.nrl.2026.502075
Eligibility for anti‐amyloid treatment in a multiethnic community‐based study
Trudel, L., Therriault, J., Macedo, A. C., Meeker, K. L., Braskie, M. N., Toga, A. W., Gauthier, S. G., Vitali, P., Schindler, S. E., O’Bryant, S. E., et al. (2026) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.70314
Lecanemab and amyloid‐related imaging abnormalities: Real‐world data from a single center experience
Wallace, A., Zhou, O., Hoang, M.-N., Porter, G., Padilla, C., & Marshall, C. D. (2026) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.70377 · Cited by 1
Yamada, K., Kurihara, M., Akitomi, Y., Sato, K., Shimasaki, R., Hatano, K., Bannai, T., Suzuki, F., Furuta, K., Tokumaru, A. M., et al. (2026) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.70374
The clinical utility of blood-based biomarkers of Alzheimer’s disease: Triumphs and pitfalls
Mir, M. M., Mir, G. M., Majid, A., Alharthi, M. H., & Alshahrani, A. M. (2026) · International review of neurobiology · doi:10.1016/bs.irn.2026.05.008
Mitigating disparities in diagnosis of dementia
Neumann, L. T. V., Mahinrad, S., Abner, E. L., Soo Borson, B., Byrd, G. S., Carrillo, M. C., Clark, L., Correro, A. N., Deters, K., Dilworth‐Anderson, P., et al. (2026) · Alzheimer s & Dementia Behavior & Socioeconomics of Aging · doi:10.1002/bsa3.70080
Sánchez‐Valle, R., Alcolea, D. A., Ferrer, G. A., Balasa, M., Naranjo, I. C., Fortea, J., Lladó, A., Lleó, A., Montes, Á. M., Lozano, L. M., et al. (2026) · Neurología (English Edition) · doi:10.1016/j.nrleng.2026.502075
From clinical trial to clinical experience: Lecanemab therapy in a real‐world case series
Sonson, M., Yadollahikhales, G., Flores, A., Lasner, I., Lee, S., Tan, Z. S., Quach, C., & Kremen, S. A. (2026) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.70365
Schulman, D. J., Jannati, A., Talkar, T., Libon, D. J., Swenson, R., Higgins, C., Pascual‐Leone, Á., & Tobyne, S. M. (2026) · doi:10.2196/preprints.102670
Neurodegenerative Disease: From Molecular Basis to Therapy, 3rd Edition
Ricci, C. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27114926
Neue biomarkergestützte Alzheimerbehandlung
Goedecke, J., Fink, G. R., & Onur, O. A. (2026) · DNP – Die Neurologie & Psychiatrie · doi:10.1007/s15202-026-6702-3
Rashidi‐Ranjbar, N., Churchill, N. W., Jerkić, M., Zomorrodi, R., Rotstein, O. D., Schneider, R., Andreazza, A. C., Rajji, T. K., Graham, S. J., Munoz, D. G., et al. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261453911
Kuroda, Y., Goto, A., Shindo, Y., Koyama, Y., & Suzuki, K. (2026) · BMC Public Health · doi:10.1186/s12889-026-28068-8
Carrasco, M., Guzman, L., Barroso, E., Olloquequi, J., Cano, A., Ureña, J., Verdaguer, E., Prohens, R., Fortuna, A., Auladell, C., et al. (2026) · GeroScience · doi:10.1007/s11357-026-02321-9
Carlisle, T. C., Holden, S. K., Sillau, S., Unger, J. R., Lafreniere, M., Bettcher, B. M., Molden, J., Nachiappan, M., Tanabe, J., Nair, K. V., et al. (2026) · Neurology and Therapy · doi:10.1007/s40120-026-00957-5
Metadata
- Authors
- Cummings, J., Apostolova, L., Rabinovici, G. D., Atri, A., Aisen, P., Greenberg, S., Hendrix, S., Selkoe, D., Weiner, M., Petersen, R. C., & Salloway, S.
- Affiliations
- Indiana University Indianapolis (US)
- University of California, San Francisco (US)
- Banner Health (US)
- University of Southern California (US)
- Harvard University (US)
- Brigham and Women's Hospital (US)
- Mayo Clinic (US)
- Brown University (US)
- Venue
- The Journal of Prevention of Alzheimer's Disease
- Publisher
- Elsevier BV
- Published
- 2023-09
- Volume
- 10
- Issue
- 3
- Pages
- 362-377
- ISSN
- 2274-5807 (ISSN-L)
- PMC
- PMC10313141
- OpenAlex
- W4360591479
- Cited by
- 961
- References
- 62
- Citations by year
- 2026: 335 · 2025: 305 · 2024: 249 · 2023: 71
- FWCI
- 170.48
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- The Journal of Prevention of Alzheimer s Disease (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion, cc-by)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- IUScholarWorks (Indiana University) (submittedVersion)
- Funders
- Foundation for the National Institutes of Health (R35AG71476, U01NS093334, P20GM109025, P30AG072959, P30 AG010133, R01AG053798, R01 AG057739)
- Alzheimer's Association (P30 AG010133)
- Alzheimer's Drug Discovery Foundation (P20GM109025)
- Eli Lilly and Company (P20GM109025)
- Biogen (P20GM109025)
- University of Southern California (P20GM109025)
- Patient-Centered Outcomes Research Institute
- Alnylam Pharmaceuticals
- BioClinica (P20GM109025)
- Sunovion
- Buck Institute for Research on Aging
- Prothena
- University of Oxford
- Eisai (P20GM109025)
- Novo Nordisk
- Shionogi
- H. Lundbeck A/S (P20GM109025)
- Grifols
- Nestec
- National Institutes of Health (RD005665)
- Genentech (P20GM109025)
- Allergan
- Avid Radiopharmaceuticals
- National Institute on Aging (AG010133, P30AG010133, U01AG057195, NIA U01 AG057195, R01AG053798, P20AG068053, NIA P30 AG010133, R01AG057739, R35AG71476, P30AG072959, P30AG072980, R35AG071476)
- National Institute of General Medical Sciences (P20GM109025)
- National Institute of Neurological Disorders and Stroke (U01NS093334)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- lecanemab, Alzheimer's disease, amyloid-related imaging abnormalities, amyloid plaques, mild cognitive impairment, early Alzheimer's disease, bleeding risk, anticoagulation, infusion reactions, monoclonal antibody therapy, caregiver-patient communication, clinical preparedness
- MeSH terms
- Alzheimer Disease, Amyloid, Antibodies, Monoclonal, Humans, Apolipoprotein E4, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
